March 5, 2018

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sirs,

Sub: Clarification on news item appeared on www.moneycontrol.com & www.bloombergquint.com dated March 5, 2018 -"US FDA observations - Aurobindo Unit 4 inspected by US FDA from Feb 12-20 and issues 9 observations.

Ref : BSE Letter No. L/SURV/ONL/RV/ZS/(2017-2018)/279 dated March 5, 2018
NSE Letter No.NSE/CM/Surveillance/7339 dated March 5, 2018

This is with reference to your above cited letter dated March 5, 2018, seeking clarification on the subject matter. In this regard we would like to inform that the United States Food and Drug Administration (US FDA) has conducted an inspection at the Company's Unit IV, a formulation manufacturing facility located at Pashamylaram, Hyderabad from 12th February 2018 to 20th February 2018. This is a scheduled inspection and at the end of the inspection, we were issued a Form 483 with 9 observations and:

- none of the observations are related to data integrity or repetitive in nature and
- we are in the midst of providing a comprehensive response to the observations and would be replying to the FDA within 15 working days from the date of closure (20th February, 2018) of audit.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary